Same-Day Discharge Post–Transcatheter Aortic Valve Replacement During the COVID-19 Pandemic : The Multicenter PROTECT TAVR Study

Archive ouverte

Barker, Madeleine | Sathananthan, Janarthanan | Perdoncin, Emily | Devireddy, Chandan | Keegan, Patricia | Grubb, Kendra | Pop, Andrei | Depta, Jeremiah | Rai, Devesh | Abtahian, Farhad | Spence, Mark | Mailey, Jonathan | Muir, Douglas | Russo, Mark | Pineda-Salazar, Jennifer | Okoh, Alexis | Smith, Meghan | Dahle, Thom | Rana, Masud | Alfadhel, Mesfer | Meier, David | Chatfield, Andrew | Akodad, Mariama | Chuang, Anthony | Samuel, Rohit | Nestelberger, Thomas | Mcalister, Cameron | Lauck, Sandra | Webb, John | Wood, David

Edité par CCSD ; Elsevier/American College of Cardiology -

International audience. Objectives: The aim of this study was to determine the safety and efficacy of same-day discharge (SDD) after transcatheter aortic valve replacement (TAVR) during the COVID-19 pandemic.Background: The COVID-19 pandemic has placed significant stress on health care systems worldwide. SDD in highly selected TAVR patients can facilitate the provision of essential cardiovascular care while managing competing COVID-19 resource demands.Methods: Patient selection for SDD was at the discretion of the local multidisciplinary heart team, across 7 international sites. The primary outcome was a composite of cardiovascular death, stroke, myocardial infarction, all-cause readmission, major vascular complications, and new permanent pacemaker (PPM) implantation.Results: From March 2020 to August 2021, 124 of 2,100 patients who underwent elective transfemoral TAVR were selected for SDD. The average age was 78.9 ± 7.8 years, the median Society of Thoracic Surgeons score was 2.4 (IQR: 1.4-4.2), and 32.3% (n = 40) had preexisting PPMs. There were no major vascular complications, strokes, or deaths during the index admission. One patient (0.8%) required PPM implantation for complete heart block and was discharged the same day. No patient required a PPM between discharge home and 30-day follow-up. The composite of cardiovascular death, stroke, myocardial infarction, all-cause readmission, major vascular complications, and new PPM at 30 days occurred in 5.7% patients (n = 6 of 106).Conclusions: SDD post-TAVR is safe and feasible in selected patients at low risk for adverse clinical events postdischarge. This strategy may have a potential role in highly selected patients even when the COVID-19 pandemic abates.

Consulter en ligne

Suggestions

Du même auteur

Leaflet and Neoskirt Height in Transcatheter Heart Valves

Archive ouverte | Akodad, Mariama | CCSD

International audience. Transcatheter heart valves (THVs) have the potential to degenerate and may require reintervention. In the case of redo transcatheter aortic valve replacement for failed THV, the leaf-lets of ...

Transcatheter solutions for transcatheter aortic valve replacement dysfunction: is redo transcatheter aortic valve replacement a durable option?

Archive ouverte | Chatfield, Andrew | CCSD

International audience. As transcatheter aortic valve replacement (TAVR) expands into a younger and lower risk cohort of patients, many important clinical questions are raised, including the one of overall valve dur...

Failure of Complete Rewrap of a Noncompliant Valvuloplasty Balloon Complicating a Transcatheter Valve-in-Valve Procedure

Archive ouverte | Chatfield, Andrew | CCSD

International audience

Chargement des enrichissements...